All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
The mm Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mm Hub cannot guarantee the accuracy of translated content. The mm and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mm content recommended for you
NICE approves lenalidomide in front-line multiple myeloma treatment
The National Institute for Health and Care Excellence in the United Kingdom (UK) has backed the use of lenalidomide in patients with previously untreated multiple myeloma (MM) who are not eligible for transplant.1,2 The decision comes four years after the European Medicines Agency (EMA) approved lenalidomide in the same indication.2,3
Background
Currently, thalidomide-based therapy is the standard of care for NDMM. In patients for whom thalidomide is contraindicated or not tolerated, bortezomib-based therapies are used. Bortezomib-based therapies, in combination with an alkylating agent and corticosteroid, may cause side effects and reduce the number of options available to the patient later in the treatment pathway.1
The evidence to support the decision comes from:
- FIRST trial; an open label, randomized trial4
- Continuous len + dex (Rd, n = 535) versus melphalan + prednisone + thalidomide (MPT, n = 547)
- Significant increase in PFS with Rd vs MPT: HR = 0.69 (95%CI, 0.59-0.79); P < 0.00001
- Patients who were treated with bortezomib-based therapy after Rd, displayed better-quality responses to second-line treatment than those who received bortezomib-based therapy after MPT
- The results of this trial supported the use of Rd as upfront therapy in MM
- An indirect comparison between len + dex and bortezomib + melphalan + prednisone (VMP)1
- Overall survival was improved in the len + dex arm compared to VMP arm (hazard ratio: 0.70, 95% CI, 0.5-0.98), as was PFS (hazard ratio: 0.74, 95% CI, 0.52-1.05)
This means that lenalidomide (len) will now be available in combination with dexamethasone (dex) for the treatment of patients who are not eligible for transplant, who are treatment naïve (newly diagnosed MM [NDMM]) and for whom thalidomide is contraindicated or not tolerated. The estimated number of patients expected to benefit is 2,100.2
References
Your opinion matters
Are you currently re-using anti-CD38 therapy in patients with multiple myeloma who have been previously exposed but were not refractory to it?